Scarica l'app Stockscreener
1.75
44.79%
-1.42
Dopo l'orario di chiusura:
1.75
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.17
Aprire:
$1.94
Volume 24 ore:
111.99M
Relative Volume:
9.94
Capitalizzazione di mercato:
$1.17B
Reddito:
$32.77M
Utile/perdita netta:
$-440.22M
Rapporto P/E:
-1.0479
EPS:
-1.67
Flusso di cassa netto:
$-400.48M
1 W Prestazione:
-50.00%
1M Prestazione:
-46.48%
6M Prestazione:
-83.47%
1 anno Prestazione:
-86.99%
Intervallo 1D:
$1.65
$1.985
Intervallo di 1 settimana:
$1.65
$3.73
Portata 52W:
$1.65
$13.20
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
1.75 | 1.17B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Market Today: Trade Desk Surges on Strong Earnings; Iovance Biotherapeutics Plummets - GuruFocus
JMP Securities Downgrades Iovance Biotherapeutics (BIT:1IOVA) - Nasdaq
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IO - GuruFocus
Iovance Biotherapeutics (IOVA) Stock Rating Maintained, Price Ta - GuruFocus
JMP Securities Downgrades Iovance Biotherapeutics (LSE:0JDK) - Nasdaq
Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - Business Wire
Securities Fraud Investigation Into Iovance Biotherapeutics, Inc. (IOVA) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss an - GuruFocus
Iovance stock plummets after lowered full-year guidance, missed analyst expectations for Amtagvi - Endpoints News
Iovance Biotherapeutics (IOVA) Shares Plummet on Revenue Miss and Forecast Cut - GuruFocus
Iovance falls after guidance cut, revenue miss - MSN
Iovance stock falls after guidance cut, Q1 miss (IOVA:NASDAQ) - Seeking Alpha
Why Iovance Biotherapeutics Stock Is Crashing Today - AOL.com
Iovance Biotherapeutics (IOVA) Downgraded by JMP Securities | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Stock Sinks 46%. Here’s Why the Biotech Is Tumbling. - Barron's
Why Iovance (IOVA) Stock Is Plummeting Today - GuruFocus
Iovance Biotherapeutics (IOVA) Price Target Cut by TD Cowen | IOVA Stock News - GuruFocus
Expert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts - Benzinga
Iovance Biotherapeutics (IOVA) Downgraded Amid Concerns Over Lau - GuruFocus
No Excuses, Iovance Biotherapeutics' Amtagvi Launch Has Underperformed (NASDAQ:IOVA) - Seeking Alpha
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% On '25 View Cut - Barchart.com
Sector Update: Health Care - marketscreener.com
Baird Downgrades Iovance Biotherapeutics to Neutral From Outperform, Adjusts Price Target to $3 From $20 - marketscreener.com
Iovance Biotherapeutics (IOVA) Price Target Cut Following Revised Revenue Outlook | IOVA Stock News - GuruFocus
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut - Zacks Investment Research
Iovance Biotherapeutics (IOVA) Price Target Lowered by HC Wainwright | IOVA Stock News - GuruFocus
Iovance Biotherapeutics (IOVA) Target Price Reduced but Buy Rating Maintained | IOVA Stock News - GuruFocus
Iovance Biotherapeutics: Q1 Earnings Snapshot - New Haven Register
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for First Quarter 2025 - GlobeNewswire
Iovance Biotherapeutics Q1 Loss Narrows, Revenue Rises - marketscreener.com
Iovance Biotherapeutics Reports Q1 2025 Financial Results - TipRanks
Iovance Biotherapeutics Inc (IOVA) Q1 2025 Earnings Call Highlights: Strong Revenue from Antagy ... - Yahoo Finance
Decoding Iovance Biotherapeutics Inc (IOVA): A Strategic SWOT Insight - GuruFocus
(IOVA) Technical Data - news.stocktradersdaily.com
Iovance Biotherapeutics (IOVA) Projects Revenue Growth and Expanded Market Reach - GuruFocus
Iovance Biotherapeutics: Buy Rating Amid Signs of Recovery and Growth Potential - TipRanks
Iovance revises 2025 revenue guidance to $250M-$300M amid ATC expansion - MSN
Iovance Biotherapeutics earnings missed by $0.12, revenue fell short of estimates - Investing.com Canada
Earnings call transcript: Iovance Biotherapeutics misses Q1 2025 EPS forecasts, stock drops - Investing.com
Iovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
IOVANCE BIOTHERAPEUTICS, INC. SEC 10-Q Report - TradingView
Iovance Biotherapeutics (IOVA) Q1 2025 Earnings Miss Estimates - GuruFocus
Iovance (IOVA) Misses Q1 Revenue Expectations, Projects Growth in Q2 | IOVA Stock News - GuruFocus
Iovance Biotherapeutics Inc Reports Q1 2025 Earnings: EPS Misses at -$0.36, Revenue Falls Short at $49.3 Million - GuruFocus
Iovance Biotherapeutics (IOVA) Sees Increased Options Activity A - GuruFocus
Earnings Flash (IOVA) Iovance Biotherapeutics Reports Q1 Revenue $49.3M, vs. FactSet Est of $82.4M - marketscreener.com
Uncovering Potential: Iovance Biotherapeutics's Earnings Preview - Nasdaq
Iovance Biotherapeutics (NasdaqGM:IOVA) Sees 3% Price Increase Over Last Month - Yahoo Finance
Iovance Biotherapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Iovance Biotherapeutics’ SWOT analysis: promising immunotherapy stock faces challenges - Investing.com
My 3 Favorite Stocks to Buy Right Now - The Motley Fool
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):